Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – Here’s What Happened

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) shares gapped up prior to trading on Monday . The stock had previously closed at $8.54, but opened at $9.05. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.81, with a volume of 3,202 shares traded.

Shionogi & Co., Ltd. Unsponsored ADR Stock Up 3.7%

The company’s fifty day moving average is $8.38 and its 200-day moving average is $8.56. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.74 and a current ratio of 6.44. The company has a market capitalization of $14.97 billion, a PE ratio of 13.75, a price-to-earnings-growth ratio of 2.00 and a beta of 0.19.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last issued its earnings results on Monday, October 27th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.02. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 39.53% and a return on equity of 11.90%. The company had revenue of $740.85 million during the quarter, compared to the consensus estimate of $742.35 million. As a group, analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.